Skip to main content
. 2015 Dec 8;10(12):e0144338. doi: 10.1371/journal.pone.0144338

Fig 5. PKR inhibition prevents C/EBPβ and eIF4B expression.

Fig 5

(A) THP-1 cells were incubated with PMA ± 1 μM PKR inhibitor (PKR-I) up to 24 h, and the levels of LAP*/LAP were determined (n = 3). (B) THP-1 cells were incubated ± PMA up to 24 h, and the levels of LAP*/LAP, (p-)PKR, and (p-)eIF2α were measured (n = 3). (C) THP-1 cells were exposed to PKR-I and/or PMA as indicated, and LAP*/LAP, (p-)eIF4B, and eIF4A levels were analysed (n = 3). (D) MM-6 cells were treated as indicated, and the levels of LAP*/LAP, (p-)eIF4B, and eIF4A were determined (n = 3). (E) THP-1 cells were incubated with VitD3 (72 h) and increasing doses of PKR-I and LAP*/LAP protein amounts were analysed (n = 3). Lanes showing the effect of PKR-I on unstimulated cells have been removed (thin line).